Amgen and ONSEdge Partner With Cancer Survivor Jan Ping for New Campaign
‘Coping with Cancer from the Outside In’ Program to Launch at the Annual Oncology Nursing Society Congress
EGFR inhibitor therapy aims to interrupt tumor growth by disrupting signals sent from the epidermal growth factor receptor, which is found on the surface of some cancer cells. Because EGFR is also present on other normal cells in the body, including skin cells, skin rash occurs in up to 90 percent of patients undergoing treatment with an EGFR inhibitor. This can be serious and potentially life threatening. Further, in its mild-to-moderate state, skin rash can cause patients physical discomfort and take an emotional toll, affecting body image. For most patients these side effects are mild, but moderate or severe toxicities that lead to dose modification or interruption develop in 8-17 percent of patients. Other appearance-related side effects include nail changes, skin cracking and hair disorders.
“Oncology nurses serve as a patient’s advocate and help them manage the side effects of cancer therapy,” said
The campaign will kick off at the Annual ONS Congress on
Following the campaign launch at the Annual ONS Congress, local training seminars will also be held in the second half of this year in
Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science’s promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics has changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people’s lives. To learn more about our pioneering science and our vital medicines, visit www.amgen.com.
CONTACT: Amgen, Thousand Oaks Christine Regan: 805-447-5476 (media) Arvind Sood: 805-447-1060 (investors)